Physician profile
Kumar Mukerjee
NPI 1831380534
$878.95
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $174 · 2021: $333 · 2022: $109.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $214.24 | 2019-2021 | |
| Genzyme Corporation | $169.49 | 2019-2022 | |
| Abbvie INC. | $92.42 | 2021 | |
| Daiichi Sankyo INC. | $82.96 | 2021 | |
| Akebia Therapeutics INC | $75.26 | 2019 | |
| Intuitive Surgical, INC. | $50.00 | 2020 | |
| Amgen INC. | $48.65 | 2019 | |
| Novartis Pharmaceuticals Corporation | $45.19 | 2020 | |
| Alnylam Pharmaceuticals INC. | $40.95 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.69 | 2019 | |
| Merck Sharp & Dohme LLC | $13.56 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.54 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kumar Mukerjee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.